Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.,American Journal of Clinical Oncology

当前位置： X-MOL 学术 › Am. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-06-09 , DOI: 10.1097/coc.0000000000000841
Weijie Ma _{1,

2} , Zimu Gong ₃ , Hamzah Abu-Sbeih ₄ , Yuanzun Peng ₅ , Frederick Peng ₆ , Fangwen Zou _{2,

7} , Aline Charabaty ₈ , Pablo C Okhuysen ₉ , Jennifer L McQuade ₁₀ , Mehmet Altan ₁₁ , Hao Chi Zhang ₂ , Anusha S Thomas ₂ , Yinghong Wang ₂

Affiliation

Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province.
Departments of Gastroenterology, Hepatology, and Nutrition.
Department of Internal Medicine, Saint Joseph Hospital, Chicago, IL.
Department of Internal Medicine, University of Missouri, Kansas City, MO.
Department of Biosciences, Rice University.
Department of Internal Medicine, Baylor College of Medicine, Houston, TX.
Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, People's Republic of China.
Department of Gastroenterology, Sibley Memorial Hospital, Johns Hopkins University, Washington, DC.
Infectious Diseases, Infection Control, and Employee Health.
Melanoma Medical Oncology.
Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center.

Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and outcome of IMDC remains unclear.

中文翻译：